Original article

Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment

Expand
  • 1. Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2. Department of Plastic and Reconstructive Surgery, Shanghai 9th People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200011, China

Received date: 2022-08-24

  Online published: 2023-06-06

Abstract

Objective To evaluate the safety of immediate breast reconstruction using deep inferior epigastric perforator (DIEP) flaps in the patients after neoadjuvant treatment. Methods From January 2019 to February 2021, the data of patients with breast cancer undergoing total mastectomy and immediate breast reconstruction using DIEP flap in Comprehensive Breast Health Center, Department of General Surgery, Ruijin Hospital were collected. Comparison of clinicopathological features was done between neoadjuvant treatment group and control group. Univariate analysis was used to compare the rate of surgical complications between two groups. Results A total of 110 patients were enrolled with 23 cases (20.9%) in neoadjuvant treatment group and 87 cases (79.1%) in control group. None of carcinoma in situ (0 vs. 19.5%, P=0.003) and higher pTNM stage (P<0.001) was present in neoadjuvant treatment group compared with those in control group. However, there were no significant differences in the number of flap perforator of DIEP (P=0.472), the proportion of bipedicled flaps (P=0.489), operative time (P=0.651) and hospital length of stay (P=0.275) between two groups. No significant difference was found in the incidence of postoperative complications between two groups. Breast seroma was the most common recipient complication (13.0%, 3 cases) without donor complication in neoadjuvant treatment group. The most common complication was fat necrosis (12.6%, 11 cases) in recipient site and abdominal seroma (3.4%, 3 cases) in donor site of control group. Reoperation was done in one case (4.3%) of neoadjuvant treatment group and 4 cases (4.6%) of control group. DIEP flap necrosis with total flap loss occurred in 2 cases (2.3%) in control group, but none in neoadjuvant treatment group. Conclusions The imme-diate breast reconstruction with epigastric free flap for breast cancer patients after neoadjuvant treatment would be a safe surgical scheme.

Cite this article

GAO Weiqi, ZHANG Xu, WANG Zheng, ZHU Yifei, HUANG Jiahui, HONG Jin, ZHU Siji, CHEN Xiaosong, HUANG Ou, HE Jianrong, CHEN Weiguo, LI Yafen, SHEN Kunwei, XU Hua, WU Jiayi . Safety analysis of immediate breast reconstruction with deep inferior epigastric perforator after neoadjuvant treatment[J]. Journal of Surgery Concepts & Practice, 2023 , 28(02) : 147 -151 . DOI: 10.16139/j.1007-9610.2023.02.11

References

[1] 刘春军, 栾杰. 腹部皮瓣:乳腺癌术后乳房再造的金标准[J]. 中华整形外科杂志, 2021, 37(7):709-711.
[1] LIU C J, LUAN J. Abdominal flap: gold standard in post-mastectomy breast reconstruction[J]. Chin J Plast Surg, 2021, 37(7):709-711.
[2] BURSTEIN H J, CURIGLIANO G, THüRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10):1216-1235.
[3] ADACHI Y, OKUMURA S, SAWAKI M, et al. Effects of neoadjuvant chemotherapy on operative adverse events and chemotherapy and radiotherapy in patients under-going immediate breast reconstruction[J]. Breast Cancer, 2020, 27(4):716-723.
[4] DE LA CRUZ L, MOODY A M, TAPPY E E, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review[J]. Ann Surg Oncol, 2015, 22(10):3241-3249.
[5] WU Z Y, KIM H J, Lee J W, et al. Long-term oncologic outcomes of immediate breast reconstruction vs. conventional mastectomy alone for breast cancer in the setting of neoadjuvant chemotherapy[J]. JAMA Surg, 2020, 155(12):1142-1150.
[6] VVRGHESE J, GOHARI S S, RIZKI H, et al. A syste-matic review and meta-analysis on the effect of neoadjuvant chemotherapy on complications following immediate breast reconstruction[J]. Breast, 2021, 55:55-62.
[7] KRACOFF S, ALLWEIS T M, BEN-BARUCH N, et al. Neo-adjuvant chemotherapy does not affect the immediate postoperative complication rate after breast reconstruction[J]. Breast J, 2019, 25(3):528-530.
[8] ZWEIFEL-SCHLATTER M, DARHOUSE N, ROBLIN P, et al. Immediate microvascular breast reconstruction after neoadjuvant chemotherapy: complication rates and effect on start of adjuvant treatment[J]. Ann Surg Oncol, 2010, 17(11):2945-2950.
[9] 李日涵, 韩思源, 金锋. 新辅助化疗对假体或扩张器植入即刻乳房重建术患者预后的影响[J]. 中国医科大学学报, 2022, 51(4):370-374.
[9] LI R H, HAN S Y, JIN F. Effect of neoadjuvant chemotherapy on the prognosis of patients with implant-or expender-based immediate breast reconstruction[J]. J Chin Med Univ, 2022, 51(4):370-374.
[10] 陈铭, 吴炅. 乳腺癌新辅助治疗与乳房重建研究进展[J]. 中国癌症防治杂志, 2020, 12(5):516-520.
[10] CHEN M, WU J. Research progress of neoadjuvant therapy and breast reconstruction for breast cancer[J]. Chin J Oncol Prev Treat, 2020, 12(5):516-520.
[11] YANG J R, KUO W L, YU C C, et al. Reconstructive outcome analysis of the impact of neoadjuvant chemotherapy on immediate breast reconstruction: a retrospective cross-sectional study[J]. BMC Cancer, 2021, 21(1):522.
[12] MEHRARA B J, SANTORO T D, ARCILLA E, et al. Complications after microvascular breast reconstruction: experience with 1195 flaps[J]. Plast Reconstr Surg, 2006, 118(5):1100-1109.
[13] BEUGELS J, MEIJVOGEL J L W, TUINDER S M H, et al. The influence of neoadjuvant chemotherapy on complications of immediate DIEP flap breast reconstructions[J]. Breast Cancer Res Treat, 2019, 176(2):367-375.
Outlines

/